← Back to Clinical Trials
Recruiting NCT02249923

NCT02249923 Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT02249923
Status Recruiting
Phase
Sponsor New York Medical College
Condition Pulmonary Vascular Disease
Study Type OBSERVATIONAL
Enrollment 2,500 participants
Start Date 2014-10
Primary Completion 2030-12

Eligibility & Interventions

Sex All sexes
Min Age 1 Day
Max Age 21 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 2,500 participants in total. It began in 2014-10 with a primary completion date of 2030-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Patients are being asked to be in this research study because medical researchers hope that by gathering information about a large number of children with pulmonary hypertension over time, their understanding of the disease process will increase and lead to better treatment. Investigators believe that pulmonary hypertension in children is different than pulmonary hypertension in adults and this study will help us understand those differences.

Eligibility Criteria

Inclusion Criteria: * The subject's age of onset of pulmonary hypertension must be prior to age 18 years * The person providing consent must be able to read either Spanish or English. * The subject (and/or parent/legal guardian) must be able to provide informed consent Exclusion Criteria: * Diagnosed with pulmonary hypertension after age 18 * Refusal to sign informed consent

Contact & Investigator

Central Contact

Erika B Rosenzweig, MD

✉ Erika.BermanRosenzweig@wmchealth.org

📞 914-493-6160

Principal Investigator

Steven H Abman, MD

PRINCIPAL INVESTIGATOR

Children's Hospital Colorado

Frequently Asked Questions

Who can join the NCT02249923 clinical trial?

This trial is open to participants of all sexes, aged 1 Day or older, up to 21 Years, studying Pulmonary Vascular Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT02249923 currently recruiting?

Yes, NCT02249923 is actively recruiting participants. Contact the research team at Erika.BermanRosenzweig@wmchealth.org for enrollment information.

Where is the NCT02249923 trial being conducted?

This trial is being conducted at Palo Alto, United States, San Francisco, United States, Aurora, United States, St. Petersburg, United States and 10 additional locations.

Who is sponsoring the NCT02249923 clinical trial?

NCT02249923 is sponsored by New York Medical College. The principal investigator is Steven H Abman, MD at Children's Hospital Colorado. The trial plans to enroll 2,500 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology